ReviewChemistry & biodiversity2026
The Incredible Potential of Cave Actinobacteria in Finding New Antimicrobials and Bioactive Compounds.
Review in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance is a growing threat that is going to be a leading cause of mortalities in the near future. In the fight against AMR, actinobacteria are historically the leading producers of antibiotics and other bioactive compounds. However, the recurrent isolation of previously discovered compounds from traditional soil actinobacteria has somewhat lessened the impact of actinobacteria. Actinobacteria from underexplored habitats such as caves still possess treasures of wonderful compounds that can be of incredible potential for the discovery of new antimicrobials. Their adaptation to extreme, nutrient-limited cave environments often drives the evolution of unique biosynthetic pathways and cryptic gene expression. In this review, we have discussed some of the recent hallmarks of actinobacteria studies conducted on caves, ranging from their diversity in caves to their metabolomic potential, with the actual isolation of a variety of bioactive compounds. We highlighted the remarkable microbial diversity within cave ecosystems, where actinobacteria often dominate and exhibit potential for producing novel antimicrobial, anticancer, and agro-active metabolites. By integrating genomics, metabolomics, tandem mass spectrometry-based molecular networking, WGS, and bioinformatics pipelines, researchers can now predict, prioritize, and characterize novel compounds more efficiently than ever before. Cave actinobacteria are invaluable and largely untapped reservoir for next-generation antibiotics and drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.